pharmafile | May 6, 2022 | Appointment | |
BIOCAPTIVA has announced the appointment of Alison Williamson as Chief Financial Officer, and member of the board.
Alison has over 30 years’ experience in financial strategy, M&A, business planning, risk management, and financial modelling. Prior to joining BIOCAPTIVA, Alison was CFO at DYSIS Medical Ltd, a global medical device business developing cancer screening technologies.
Jeremy Wheeler, CEO of BIOCAPTIVA, said: “I am delighted to welcome Alison to the Board and senior team at BIOCAPTIVA. Alison has a strong track record of fund raising, and successful exits through her career in med-tech which will be hugely important as we enter our next growth phase. As we look to start the first in human trial with the BioCaptis, Alison’s commercial awareness and operational expertise will be critical in supporting the path ahead for the company.
“BIOCAPTIVA has made significant progress since spinning out of the University of Edinburgh just over a year ago. I am confident that the company, with the valuable addition of Alison to the team, will continue to forge ahead as we have demonstrated in our first year of operations.”